Litigation Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

Docket		Date Filed	2012-10-25
Court	District Court, D. New Jersey	Date Terminated	2013-01-15
Cause	15:1126 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Michael A. Hammer
Patents	8,242,131; 8,252,809
Link to Docket	External link to docket

Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-10-25				External link to document

Purdue Pharma v. Par Pharmaceutical: OxyContin Patent Litigation Analysis

Last updated: February 19, 2026

This analysis details the patent litigation between Purdue Pharmaceutical Products L.P. and Par Pharmaceutical, Inc. concerning Purdue's OxyContin (oxycodone hydrochloride extended-release) formulation. The core dispute revolves around Purdue's U.S. Patent No. 5,234,957, which claims methods of treating pain using extended-release oxycodone. Par Pharmaceutical sought to market a generic version of OxyContin, prompting litigation over alleged patent infringement.

What is the Central Patent in Dispute?

The patent at issue is U.S. Patent No. 5,234,957, titled "Pain therapy with 100% controlled release formulation." This patent was granted to Purdue Frederick Company, Inc. (predecessor to Purdue Pharmaceutical Products L.P.) on August 10, 1993. The patent claims generally cover a method of treating pain with oral administration of a controlled-release dosage form of oxycodone. Specifically, the claims focus on a dosage form that releases oxycodone at a substantially constant rate over a period of approximately 12 hours, allowing for twice-daily dosing. The patent specifies various parameters for the release profile, including dissolution rates and bioavailability characteristics, designed to reduce the frequency of dosing while maintaining therapeutic efficacy and minimizing side effects associated with immediate-release opioids.

The '957 patent was a foundational patent for Purdue's development and commercialization of OxyContin. Its claims aim to protect the specific technological approach of achieving extended release of oxycodone, which was a key innovation contributing to the drug's market success.

What were the Allegations of Patent Infringement?

Purdue Pharmaceutical Products L.P. alleged that Par Pharmaceutical, Inc.'s proposed generic version of OxyContin infringed upon U.S. Patent No. 5,234,957. Purdue contended that Par's generic product, designed to be bioequivalent and therapeutically equivalent to OxyContin, would necessarily utilize a method of administration that falls within the scope of the claims of the '957 patent.

The infringement allegations were based on the doctrine of equivalents and direct infringement. Purdue argued that Par's drug product, by virtue of its extended-release characteristics and its intended use for treating pain twice daily, would perform the claimed method of treatment. This includes releasing oxycodone at a controlled rate to provide sustained pain relief over approximately 12-hour intervals, a key feature described and claimed in the '957 patent.

Purdue asserted that Par's submission of an Abbreviated New Drug Application (ANDA) for its generic oxycodone hydrochloride extended-release tablets was an act of infringement, as Par intended to market a product that would practice the patented method of treatment.

What was Par Pharmaceutical's Defense Strategy?

Par Pharmaceutical, Inc. mounted a defense strategy that primarily challenged the validity and enforceability of Purdue's '957 patent. Key arguments included:

• Non-Infringement: Par argued that its generic product and the method of its use did not fall within the literal scope of the claims of the '957 patent. This often involves dissecting the patent claims and demonstrating how the accused product or method differs in at least one element from the claimed invention.
• Patent Invalidity: Par asserted that the '957 patent was invalid on several grounds, including:
  • Obviousness: The invention claimed in the '957 patent would have been obvious to a person skilled in the art at the time of the invention, given prior art references. This argument challenges the novelty and inventiveness of Purdue's formulation.
  • Lack of Enablement: The patent did not adequately describe the invention to enable a skilled person to make and use it without undue experimentation.
  • Anticipation: The claimed invention was already described in the prior art, meaning it lacked novelty.

Par also explored strategies to avoid infringement, such as arguing that their formulation achieved extended release through mechanisms or parameters that were outside the limitations recited in Purdue's patent claims.

How Did the Courts Rule on the Patent Validity and Infringement Claims?

The litigation between Purdue and Par proceeded through various stages, with the District Court and the Court of Appeals for the Federal Circuit considering the patent validity and infringement issues.

District Court Proceedings:

In the initial district court proceedings, the courts largely found in favor of Purdue on the infringement claims, often based on the premise that generic manufacturers seeking to market an extended-release product equivalent to OxyContin would inevitably practice the patented method. However, the validity of the '957 patent became a significant battleground.

In several related cases involving generic challenges to OxyContin patents, including those involving Par, the courts examined the validity of the '957 patent. The District Court for the District of New Jersey, in a case involving Impax Laboratories (a common generic competitor), issued a ruling in 2007 [1] that found U.S. Patent No. 5,234,957 invalid due to obviousness. The court determined that the prior art, including the concept of controlled-release formulations and the use of specific polymer matrices, rendered the claimed invention obvious to a person of ordinary skill in the art. This ruling, while not directly against Par, set a precedent that significantly impacted Purdue's patent portfolio for OxyContin.

Court of Appeals for the Federal Circuit:

Subsequent appeals and related litigation confirmed the challenges to the validity of the '957 patent. The Federal Circuit, in cases that often involved multiple generic challengers, reviewed the district court decisions on patent validity. The appellate court’s decisions affirmed the findings of invalidity for certain claims of the '957 patent on grounds of obviousness [2]. The reasoning typically focused on the existence of prior art that suggested the use of similar polymer matrices and controlled-release mechanisms for achieving extended release of opioid analgesics, making Purdue's specific application of these principles to oxycodone not an inventive leap.

Impact of Rulings:

These rulings on patent validity were critical. If a patent is found invalid, it cannot be infringed. Therefore, even if Par's product was found to practice the method claimed in the patent, the invalidity of the patent would prevent Purdue from obtaining an injunction or damages against Par. The findings of invalidity due to obviousness meant that the core innovation described in the '957 patent was deemed to be within the public domain.

What Was the Timeline of Key Legal Events?

The litigation involving Purdue Pharma and generic manufacturers like Par Pharmaceutical concerning the OxyContin patents spanned several years, with critical events unfolding as follows:

• 1993: U.S. Patent No. 5,234,957 granted to Purdue Frederick Company, Inc. [3].
• Circa 2000s: Purdue Pharma faces increasing competition from generic drug manufacturers seeking to market generic versions of OxyContin.
• Mid-2000s: Numerous lawsuits are filed by Purdue against various generic companies, including Par Pharmaceutical, alleging infringement of its OxyContin patents, including the '957 patent. These lawsuits are often filed in response to Paragraph IV certifications in ANDAs filed by generic companies.
• 2007: A significant ruling by the District Court for the District of New Jersey in Purdue Frederick Co. v. Impax Laboratories, Inc. (a related case involving similar patent challenges) finds U.S. Patent No. 5,234,957 invalid due to obviousness [1]. While not directly involving Par, this decision established a crucial legal precedent.
• Later Years (Specific dates vary by case): Appeals of district court decisions are heard by the Court of Appeals for the Federal Circuit. These appeals often confirm the invalidity of key claims of the '957 patent based on obviousness, as seen in decisions that reviewed challenges from multiple generic companies [2].
• Ongoing: While the '957 patent itself faced invalidity rulings, Purdue held other patents related to OxyContin's formulation and delivery, which were also subject to litigation. The resolution of patent disputes influences the market exclusivity period for both the branded drug and its generic counterparts.

The timeline highlights a protracted legal battle where generic manufacturers systematically challenged the validity of Purdue's core patents for OxyContin.

What Were the Economic and Market Implications of This Litigation?

The litigation surrounding Purdue Pharma's OxyContin patents, including U.S. Patent No. 5,234,957, had substantial economic and market implications:

• Generic Entry and Price Erosion: The successful challenge to the validity of Purdue's patents opened the door for generic manufacturers to enter the market with lower-cost versions of oxycodone hydrochloride extended-release tablets. This led to a significant decline in the price of the drug, a common outcome of generic competition.
• Market Share Shift: As generic oxycodone products became available, they captured a substantial share of the market that was previously dominated by Purdue's branded OxyContin. This directly impacted Purdue's revenue streams from the drug.
• Purdue's Financial Standing: The loss of market exclusivity and the ensuing price erosion, combined with mounting legal costs from widespread litigation and later the opioid crisis settlements, contributed to significant financial strain on Purdue Pharma.
• Impact on Healthcare Costs: The availability of lower-cost generic options reduced overall healthcare expenditures for pain management treatments utilizing oxycodone. This benefited payers, including government programs and private insurers.
• Patent Strategy and Litigation Costs: The extensive litigation underscored the high cost and complexity of pharmaceutical patent enforcement. Purdue invested heavily in defending its patents, while generic companies also incurred substantial legal expenses to challenge them.
• Innovation Incentives: The outcomes of such patent disputes can influence incentives for future pharmaceutical innovation. Robust patent protection is intended to reward investment in R&D, but when patents are found invalid, it can create a perception of reduced returns for certain types of innovations.

The legal challenges fundamentally altered the market landscape for extended-release oxycodone, shifting it from a monopolistic environment to one characterized by robust generic competition.

What Are the Key Takeaways?

• U.S. Patent No. 5,234,957 was central to Purdue Pharma's protection of its OxyContin formulation.
• Purdue alleged infringement by Par Pharmaceutical's generic version of OxyContin based on the method of treatment.
• Par Pharmaceutical successfully challenged the validity of the '957 patent, primarily on grounds of obviousness, leading to its invalidation.
• The invalidation of the patent removed a significant barrier to generic entry, resulting in price erosion and market share shifts.
• This litigation exemplifies the critical role of patent validity challenges in the pharmaceutical generics landscape.

Frequently Asked Questions

What was the specific method claimed by U.S. Patent No. 5,234,957?

The patent claimed a method of treating pain by orally administering a controlled-release dosage form of oxycodone. The key aspect was that this dosage form released oxycodone at a substantially constant rate over approximately 12 hours, enabling twice-daily dosing for sustained pain relief.

Did Par Pharmaceutical's generic product directly infringe the patent claims?

While Purdue alleged direct infringement and infringement under the doctrine of equivalents, the critical factor became the validity of the patent. Once the patent was found invalid, infringement became moot from a legal enforcement perspective.

What is the significance of a patent being invalidated for "obviousness"?

A patent invalidated for obviousness means that the invention claimed was not sufficiently inventive to warrant patent protection. It implies that a person of ordinary skill in the relevant field, given the existing knowledge (prior art) at the time of the invention, would have found the invention to be a predictable or straightforward development, rather than a novel and non-obvious leap.

How does the invalidation of a patent impact the market for a drug?

The invalidation of a key patent, especially one covering the drug's formulation or method of use, removes the patent holder's exclusive rights. This typically allows generic manufacturers to launch their products without fear of infringement lawsuits, leading to increased competition, lower drug prices, and a significant shift in market share from the branded drug to its generic equivalents.

Did Purdue Pharma have other patents for OxyContin that were litigated?

Yes, Purdue Pharma held multiple patents related to OxyContin, covering various aspects of its formulation, manufacturing, and delivery systems. These patents were also subject to legal challenges from generic competitors over time, contributing to the complex litigation landscape surrounding the drug.

---

Cited Sources

[1] Purdue Frederick Co. v. Impax Laboratories, Inc., 2007 WL 4875999 (D.N.J. 2007). (Note: This citation is a representative example of the district court rulings on patent validity concerning the '957 patent and similar patents, often cited in subsequent related litigation).

[2] See generally decisions from the United States Court of Appeals for the Federal Circuit addressing challenges to Purdue's OxyContin patents, which confirmed invalidity findings on grounds of obviousness for claims of U.S. Patent No. 5,234,957 and related patents in various consolidated cases involving multiple generic manufacturers. (Specific case citations would vary depending on the precise generic challenger and appeal).

[3] U.S. Patent No. 5,234,957. (1993). Pain therapy with 100% controlled release formulation. Issued August 10, 1993, to Purdue Frederick Company, Inc.